Professor Sara Mangsbo

Chair of the Board

Professor Mangsbo is a co-founder of Immuneed , where she served as CEO, CSO, and board member during its early years. Currently, she holds a professorship at Uppsala University’s Department of Pharmacy, focusing on biologics. Her research expertise encompasses immunology and oncology, with an emphasis on drug development. She has significantly utilized ID.Flow in her projects, contributing to work that validated its use in predicting cytokine release and complement activation. Mangsbo has also studied drug responses in the presence of anti-drug antibodies and conducted research to ensure efficacy while avoiding infusion reactions, making her a valuable advisory board asset.

Laura Salazar Fontana, Ph.D.

Board Member

Dr. Laura I. Salazar Fontana is an immunologist with 15+ years of expertise in the immunogenicity of biotherapeutics, including peptides and cell & gene therapies. As a consultant, she specializes in assessing and mitigating adverse immune responses using a risk-based approach. Previously, as an FDA reviewer, she helped develop immunogenicity guidelines on analytical method validation (2019) and risk assessment principles (2014). Now, as an independent consultant, she prepares Immunogenicity Risk Assessments (IRA) and Integrated Summaries of Immunogenicity (ISI) for regulatory filings. She also founded LAIZ Regulatory Science Consulting SARL in Switzerland and is a full member of the European Immunogenicity Platform.

Annick de Vries, Ph.D.

Board Member

Dr. Annick de Vries is a life science leader with over 20 years of experience spanning target validation, preclinical studies and regulated bioanalysis. She previously served as Chief Scientific Officer at Sanquin Diagnostic Services, where she built and led a bioanalysis team supporting large protein assays, immune monitoring and global diagnostic services (ISO15189/IVDR). She now runs her own consultancy company Annick BioInsight Consulting. Annick is recognized as a key opinion leader in therapeutic drug monitoring (TDM) of biologics. She serves on the advisory board of COMFORT consortium as a recognized KOL in quantitative measurements in home-sampled blood. Annick got her PhD in pharmacology from Utrecht University and conducted postdoctoral research on immune–neural cross-talk at the Universities of Bristol and Edinburgh, later leading biomarker assay development at the Translational Medicine Research Collaboration (Wyeth/Pfizer). She has co-authored over 200 peer-reviewed publications, including 100+ on PK/ADA assays for biologics.